HMI 203
Alternative Names: HMI-203Latest Information Update: 27 Mar 2024
At a glance
- Originator Homology Medicines
- Developer Q32 Bio
- Class Gene therapies
- Mechanism of Action Gene transference; Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Mucopolysaccharidosis II